Interpace Biosciences, Inc.
IDXG
Interpace Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.7 million, down 17.5% from fiscal 2024. In the quarter to June 2026, revenue fell 1.09%, EPS grew 104.1% and free cash flow fell 92.1%, each against the same quarter a year earlier. Operating cash flow growth for five consecutive years.
Follow IDXG
An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Revenue |
36.14 | 36.25 | 38.73 | 41.91 |
+8 more TTM periods Free account |
Cost of Revenue |
13.10 | 13.58 | 14.60 | 15.92 | |
Gross Profit |
23.04 | 22.66 | 24.13 | 25.99 | |
R&D Expenses |
0.59 | 0.62 | 0.64 | 0.69 | |
SG&A Expenses |
18.28 | 18.67 | 19.40 | 20.73 | |
Operating Income |
4.17 | 3.38 | 4.08 | 4.57 | |
Non-operating Income/Expense |
(0.17) | (0.24) | (0.31) | (0.47) | |
| 4.00 | 3.14 | 3.77 | 4.10 | ||
Income Tax Provision |
(20.86) | (20.91) | (21.22) | 0.00 | |
Income after Tax |
24.86 | 24.06 | 24.98 | 4.10 | |
Net Income Common |
24.45 | 23.65 | 24.58 | 3.34 | |
EPS (Basic) |
26.83 | 26.11 | 27.81 | 4.34 | |
EPS (Diluted) |
5.03 | 4.30 | 4.45 | (3.59) | |
Shares (Basic, Weighted) |
2.97 | 1.80 | 0.88 | 0.88 | |
Shares (Diluted, Weighted) |
5.54 | 4.38 | 4.38 | 3.78 | |
Gross Margin |
63.75% | 62.53% | 62.31% | 62.01% | |
EBIT Margin |
11.53% | 9.32% | 10.55% | 10.90% | |
EBT margin |
11.06% | 8.65% | 9.74% | 9.77% | |
Net Profit Margin |
67.64% | 65.25% | 63.46% | 7.96% | |
Free Cash Flow Margin |
11.35% | 12.29% | 12.98% | 9.33% | |
EBITDA |
5.09 | 4.28 | 4.96 | 5.42 | |
EBIT |
4.17 | 3.38 | 4.08 | 4.57 | |
EPS (Diluted, from Cont. Ops) |
5.00 | 4.35 | 4.50 | (3.85) | |
EPS (Diluted, Consolidated) |
5.02 | 4.27 | 4.44 | (3.60) | |
EPS (Diluted, from Disc. Ops) |
0.00 | 0.00 | 0.00 | 0.00 | |
EPS (Basic, Consolidated) |
26.82 | 26.07 | 27.77 | 4.31 | |
EPS (Basic, from Discontinued Ops) |
(0.25) | (0.35) | (0.45) | (0.45) | |
Shares (Diluted, Average) |
4.38 | 4.38 | — | 3.21 | |
EPS (Basic, from Continuous Ops) |
27.10 | 26.45 | 28.25 | 4.15 | |
Income from Continuous Operations |
24.86 | 24.06 | 24.98 | 4.10 | |
Income from Discontinued Operations |
(0.41) | (0.41) | (0.41) | (0.30) | |
Consolidated Net Income/Loss |
24.45 | 23.65 | 24.58 | 3.80 | |
EBITDA Margin |
14.09% | 11.81% | 12.82% | 12.93% | |
Operating Cash Flow Margin |
12.33% | 13.46% | 15.06% | 11.64% |